LAGUNA HILLS, Calif., Nov. 29 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on the collection and banking of adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, is pleased to announced that the California Department of Public Health has renewed LifeStem's biologics license. LifeStem is the wholly-owned subsidiary of CalbaTech in the business of collecting adult stem cells for possible therapeutic autologous future use.
"Management has worked diligently to make sure that LifeStem's biologics license was renewed. As such, LifeStem's protocols and procedures have been met the standards as set by the State of California. LifeStem has recently completed training at the state-of-the-art Youthtopia Med Spa in a suburb of Atlanta, and Youthtopia is covered under our biologics license. Anyone seeking our collection service can contact LifeStem and schedule a Stem Cell Microbank(TM) Service at Youthtopia," said James DeOlden, CEO of CalbaTech.
"We are currently in discussion with entities interested in using our services for collection in Florida, and in Northern California, and we look forward to having more locations where clients can go for our service," said Mr. DeOlden.
LifeStem(TM) Inc., a CalbaTech wholly-owned subsidiary, has developed a unique process to harvest adult stem cells in micro quantities to be cryopreserved for future transplantation into the same client for medical purposes. The benefits of stem cell therapies have shown great success in the treatment of life threatening disease including chronic heart failure and cancer, with the promise of playing prominent roles in cures for other diseases such as Parkinson's, Alzheimer's and diabetes.
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, as well as providing services in the collection, processing and storage of adult stem cells.
Note: Certain statements in this news release may contain
"forward-looking" information within the meaning of rule 175 under the
Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and
are subject to the safe harbor created by those rules. We use words such as
"anticipate," "believe," "expect," "future," "intend," "plan," and similar
expressions to identify forward-looking statements. These statements
including those related to being in a large and growing market, exhibiting
rapid growth characteristics, and having a growth strategy, are forward
looking statements. These forward looking statements are only predictions
and are subject to certain risks, uncertainties and assumptions. Some of
the risks, uncertainties and assumptions that could cause actual results to
differ materially from estimates or assumptions in this press release
include the risk that we will not be able to grow our revenues and market
share, the risk that our prices do not remain competitive and the risk that
we will not achieve profitability. Additional risks are identified and
described in the Company's public filings with the Securities and Exchange
Commission, including our most recent Report on Form 10-KSB, and Reports on
Form 10-QSB and Form 8-K. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent date. The
Company's past performance is not necessarily indicative of its future
performance. The Company does not undertake, and the Company specifically
disclaims, any obligation to update any forward-looking statements to
reflect occurrences, developments, events, or circumstances after the date
of such statement.
Contact: Paul Knopick
E & E Communications
|SOURCE CalbaTech, Inc.|
Copyright©2007 PR Newswire.
All rights reserved